[
    [
        {
            "time": "",
            "original_text": "[买入评级]小分子靶向药物(医药生物行业)：医保谈判催化 竞争格局生变",
            "features": {
                "keywords": [
                    "小分子靶向药物",
                    "医药生物行业",
                    "医保谈判",
                    "竞争格局"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[买入评级]小分子靶向药物(医药生物行业)：医保谈判催化 竞争格局生变",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]